EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance

Shuang Xiang, Xiaojuan Chen, Jieying Lin, Xiaojing Lin, Qianmeng Lin, Xiaojuan Song, Ling Yan, Haoran Peng, Zhengchao Tu, Adam V Patterson, Jeff B Smaill, Yalin Tu und 2 weitere

Journal of Medicinal Chemistry · 22.01.2026 · 69 (2) · 1178-1198

DOI: 10.1021/acs.jmedchem.5c02462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.01.2026. Verfasst von Shuang Xiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization…. Hauptthemen laut MEDLINE: Drug Design, Drug Resistance, Neoplasm, Macrocyclic Compounds, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Changjiang Scholar Program, Ministry of Education, Basic and Applied Basic Research Foundation of Guangdong Province, Major Project of Guangzhou National Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alterations in the FGFR family act as oncogenic drivers for multiple pediatric and adult tumors, leading to the development and approval of several FGFR inhibitors. However, the on-target gatekeeper and “molecular brake” mutations confer clinically acquired resistance to the FDA-approved FGFR inhibitors, which presents a significant unmet medical need. Herein, we report the first novel macrocycle-based FGFR inhibitors targeting both wild-type and clinically acquired variants of the FGFR family. The representative compound 8r potently inhibited FGFR1/2/3 with IC 50 values of 10.0, 6.9, and 30.2 nM, respectively. Compound 8r also potently suppressed proliferation of a series of FGFR-driven cancer cell lines with IC 50 values of 2.0–13.3 nM. Compared with futibatinib, 8r exhibited superior inhibitory activity toward FGFR1 V561M, FGFR2 V564F, and FGFR2 N549K mutations with IC 50 values of 6.8, 0.7, and 0.8 nM, respectively. Moreover, 8r demonstrated favorable antitumor efficacy in an RT112/84 bladder cancer xenograft model. This work provides a promising macrocycle-based lead compound for the treatment of FGFR-driven cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignDrug Resistance, NeoplasmMacrocyclic CompoundsAntineoplastic AgentsReceptors, Fibroblast Growth FactorProtein Kinase InhibitorsHumansAnimalsCell Line, TumorCell ProliferationMiceStructure-Activity RelationshipMice, NudeXenograft Model Antitumor Assays

Substanzen

Macrocyclic CompoundsAntineoplastic AgentsReceptors, Fibroblast Growth FactorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE),…
  • Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland Private Bag 92019, New Zealand.

ORCID-Profile: Yongheng Chen, Xiaoyun Lu

Förderung

  • Changjiang Scholar Program, Ministry of Education
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Major Project of Guangzhou National Laboratory
  • Cancer Society Auckland Northland
  • China Maurice Wilkins Centre Collaborative Research Program

Zitieren

APA

Xiang, S., Chen, X., Lin, J., Lin, X., Lin, Q., Song, X., Yan, L., Peng, H., Tu, Z., Patterson, A. V., Smaill, J. B., Tu, Y., Chen, Y., & Lu, X. (2026). Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance. Journal of Medicinal Chemistry, 69(2), 1178-1198. https://doi.org/10.1021/acs.jmedchem.5c02462

Vancouver

Xiang S, Chen X, Lin J, Lin X, Lin Q, Song X, et al. Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance. Journal of Medicinal Chemistry. 2026;69(2):1178-1198. doi:10.1021/acs.jmedchem.5c02462

BibTeX
@article{Xiang2026,
  author = {Xiang, Shuang and Chen, Xiaojuan and Lin, Jieying and Lin, Xiaojing and Lin, Qianmeng and Song, Xiaojuan and Yan, Ling and Peng, Haoran and Tu, Zhengchao and Patterson, Adam V and Smaill, Jeff B and Tu, Yalin and Chen, Yongheng and Lu, Xiaoyun},
  title = {Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {2},
  pages = {1178--1198},
  doi = {10.1021/acs.jmedchem.5c02462}
}
Kostenlos starten →